Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2Phase NA 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 5Unknown 4Active not recruiting 3Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-small Cell Lung Cancer Metastatic 1Brain Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 90Gemcitabine 81Paclitaxel 80Docetaxel 73Capecitabine 64Oxaliplatin 53Specimen Handling 51Fluorouracil 51Magnetic Resonance Spectroscopy 49Radiotherapy 48Bevacizumab 48Dexamethasone 45Cyclophosphamide 44Leucovorin 38Drug Therapy 38Irinotecan 36Doxorubicin 36Pemetrexed 35Injections 30Trastuzumab 28Vincristine 27Rituximab 27Radiosurgery 25Prednisone 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24Lenalidomide 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × aumolertinib × Clear all
NCT07183189 2026-04-14

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
576 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Qianfoshan Hospital

Phase 3 Recruiting
98 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05800223 2023-04-05

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Shanghai Cancer Hospital, China

Phase 3 Recruiting
300 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT05768490 2023-03-14

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Sun Yat-sen University

Phase 3 Recruiting
232 enrolled
CNS

Brain Neoplasms

NCT04951635 2022-06-16

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3 Recruiting
150 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡